Summary
The in vitro activity of orally active first generation (cefalexin), second generation (cefaclor and cefuroxime) and third generation (cefdinir, cefixime, ceftibuten, cefpodoxime, cefprozil, and cefetamet) cephalosporins was reviewed. All of these cephalosporins inhibit community-acquired respiratory pathogens (i.e. Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and S. pyogenes) and Neisseriaceae, but have little or no clinically relevant activity against oxacillin-/methicillin-resistant staphylococci, enterococci, Gramnegative rods (i.e. Pseudomonas aeruginosa and Xanthomonas maltophilia), or anaerobic rods (i.e. Bacteroides fragilis and Clostridium species). Cefalexin, cefaclor and cefuroxime are less potent inhibitors and have a narrower spectrum of activity than the third generation cephalosporins reviewed. Among the third generation cephalosporins, cefixime inhibits the broadest spectrum of Enterobacteriaceae, but cefixime, ceftibuten, and cefetamet lack any clinically meaningful antistaphylococcal activity, and cefpodoxime and cefprozil are several dilution-folds less active against staphylococci than cefdinir. Cefdinir matches the potent inhibitory activity of cefixime against the most common community-acquired respiratory tract pathogens and the most common community-acquired Enterobacteriaceae (i.e. Escherichia coli, Proteus mirabilis and Klebsiella pneumoniae). In addition, of the third generation cephalosporins reviewed, cefdinir is the most potent inhibitor of the common community-acquired staphylococcal pathogens, Staphylococcus aureus, coagulase-negative staphylococci and S. saprophyticus. Thus, the spectrum of activity of cefdinir encompasses most clinically significant community-acquired pathogens.
Similar content being viewed by others
References
Finch R. Skin and soft-tissue infections. Lancet 1988; 1: 164–8
Friend JAR, Petrie JC. Respiratory Diseases. In: Speight TM, editor. Avery’s drug treatment. Chap. XX. Auckland: Adis Press Limited, 1987: 812–54
Greenwood D, Slack R. Urinary tract infection. Br J Pharmacol 1982; 13: 619–30
MacFarlane JT. Treatment of lower respiratory infections. Lancet 1987; 2: 1446–9
NCCLS. National Committee for Clinical Laboratory Standards. Tentative standard M23-T: development of in vitro susceptibility testing criteria and quality control parameters. Villanova, PA: NCCLS, 1989
NCCLS. National Committee for Clinical Laboratory Standards. Approved standard M7-A2: standard methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Villanova, PA: NCCLS, 1990
Briggs BM, Jones RN, Erwin ME, et al. In vitro activity evaluations of cefdinir (FK482, CI983, and PD134393). A novel orally administered cephalosporin. Diagn Microbiol Infect Dis 1991; 14: 425–34
Gerlach EH, Jones RN, Allen SD, et al. Cefdinir (FK 482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines. Diagn Microbiol Infect Dis 1992; 15: 537–43
Scriver SR, Willey BM, Low DE, et al. Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, Gram-negative bacilli and respiratory tract pathogens. Eur J Clin Microbiol Infect Dis 1992; 11: 646–52
Qadri SM, Ueno Y, Saldin H, et al. In vitro activity of cefdinir (FK 482, PD 134393, CL-983): a new orally active cephalosporin. Chemotherapy (Basel) 1993; 39: 112–9
Bauernfeind A, Jungwirth R, Schweighart S, et al. Antibacterial activity and stability towards new beta-lactamases of eleven oral cephalosporins. Infection 1990; 18(Suppl. 3): 155–61
Neu HC, Saha G, Chin N-X. Comparative in vitro activity and β-lactamase stability of FK482, a new oral cephalosporin. Antimicrob Agents Chemother 1989; 33: 1800–1975
Payne DJ, Amyes SGB. The sensitivity of clinical bacteria isolated in Scotland to the oral cephalosporin, cefdinir. Drugs Exp Clin Res 1992; 18: 225–31
Wise R, Andrews JM, Thornber D. The in-vitro activity of cefdinir (FK482), a new oral cephalosporin. J Antimicrob Chemother 1991; 28: 239–48
Verbist L, Verhaegen J. Comparative in vitro activity of cefdinir (CI-983, FK-482) against aerobic microorganisms. Poster presented at the 17th ICC, Berlin, Germany, June 24, 1991
Bauernfeind A, Przyklenk B, Jungwirth R, et al. Comparative activity of cefdinir (CI-983, FK-482) against staphylococci. Poster presented at the 17th ICC, Berlin, Germany, June 24, 1991
Barrett MS, Jones RN. Susceptibility testing interpretive criteria and drug stability for cefdinir, cefetamet, and cefpodoxime against Neisseria gonorrhoeae. Diagn Microbiol Infect Dis 1992; 15: 685–91
Frampton JE, Buckley MM, Brogden RN, et al. Cefpodoxime proxetil: a review of its antibacterial acativity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 889–917
Jones RN. Antimicrobial activity, spectrum and pharmacokinetics of old and new orally administered cephems. Antimicrobic Newsletter 1988; 5: 1–8
Jones RN. New oral antimicrobial agents. Curr Opin Infect Dis 1989; 2: 367–75
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jones, R.N. In Vitro Antibacterial Activity of Oral Cephalosporins. Clin. Drug Invest. 9 (Suppl 3), 22–30 (1995). https://doi.org/10.2165/00044011-199500093-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199500093-00005